DENVER, April 3 /PRNewswire-FirstCall/ -- Global Med Technologies, Inc. (OTC:GLOB) (BULLETIN BOARD: GLOB) , announced today that Sarah Ladd Eames has joined Global Med's Board of Directors as an independent board member, Chairperson of the Company's Compensation Committee, and a member of the Company's Audit Committee. (Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO ) Ms. Eames comes to the Global Med Board with a wealth of health care and business experience. Previously serving as Allied Healthcare International's (NASDAQ:AHCI) CEO, President and Chief Operating Officer, Ms. Eames is currently on the board of the $350 million health care company. Ms. Eames stated, "I am both pleased and honored to be on the Board of Global Med Technologies. Global Med is a very exciting, rapidly growing medical software company to which I believe I can make a substantial contribution." Michael I. Ruxin, M.D., Global Med's Chairman and CEO, commented, "Sarah Eames' credentials, with her specific, broad-based international experience, and her prior management positions at Johnson & Johnson, Apria Healthcare Group, Abbey Healthcare Group, and Baxter Travenol, will add immense value to the Company as it expands globally. On behalf of Global Med Technologies, I warmly welcome Sarah to our Board of Directors." About Global Med Technologies, Inc. Global Med Technologies, Inc. is an international e-Health, medical information technology company, providing information management software products and services to the healthcare industry. Its Wyndgate Technologies division is a leading supplier of information management systems to U.S. and international blood centers and hospital transfusion centers. Current clients of Wyndgate's products and services manage more than 3 million units of blood, or over 22% of the U.S. blood supply, each year. Wyndgate's products are also being implemented in Canada, the Caribbean and sub-Sahara Africa. Together, the SafeTrace Tx(R)* advanced transfusion management system and the SafeTrace(R) donor management system provide Vein-to-Vein(R) tracking from donor collection to patient transfusion. For more information about Global Med's products and services, please call 800-WYNDGATE or visit http://www.globalmedtech.com/, http://www.peoplemed.com/ and http://www.wyndgate.com/. This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release. *Patent Pending http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies, Inc. CONTACT: Michael I. Ruxin, M.D. of Global Med Technologies, Inc., +1-303-238-2000; or Investor Relations, Paul Short, President of Investment Strategies, LLC, +1-304-523-3252, for Global Med Technologies, Inc. Web site: http://www.wyndgate.com/ Web site: http://www.peoplemed.com/ Web site: http://www.globalmedtech.com/

Copyright